AstraZeneca India Q1 standalone PAT falls 32% YoY to ₹37.9 Cr as margins compress

AstraZeneca Pharma India's standalone Q1 FY27 (quarter ended June 30, 2026) revenue from operations rose 29.7% YoY to ₹682.8 Cr (₹526.3 Cr a year ago) and 18.0% QoQ (₹578.6 Cr in Q4 FY26), matching the company's own reported "30% growth" claim. But profit after tax fell 32.1% YoY to ₹37.9 Cr (₹55.8 Cr in Q1 FY26) and 15.5% QoQ (₹44.9 Cr in Q4 FY26), with EPS down to ₹15.17 from ₹22.33 a year earlier. The divergence between strong top-line growth and a shrinking bottom line is the story of the quarter. Operating profitability (profit before exceptional items and tax, as % of revenue) nearly halved to 7.5% from 15.3% a year ago and 10.3% last quarter; net margin fell to 5.6% from 10.4% YoY. The squeeze sits mainly on cost of goods and opex: purchase of stock-in-trade plus inventory movement together consumed ₹4,472 Mn of the ₹6,410 Mn total expense base, up sharply from ₹2,859 Mn a year ago, while employee benefit expense rose 22.8% YoY to ₹791.6 Mn — both outpacing revenue growth. A small exceptional charge of ₹2.4 Mn (site-exit related, Note 5) was booked, similar to ₹3.6 Mn a year ago, so it barely moves the growth math either way. Segment-wise, Oncology revenue grew 26% YoY to ₹464.9 Cr, Biopharmaceuticals (CVRM, R&I, V&I) grew 36% to ₹161.9 Cr, and Rare Diseases surged 35x to ₹14.4 Cr off a small base. Management gives no formal FY27 guidance or margin target on record, so this print cannot be measured against a stated company outlook. Our pre-result preview had pegged Q1 revenue at just ₹290-310 Cr and PAT at ₹24-28 Cr with an 8-9% margin watch band; actual revenue and PAT both came in well above that range, but the preview bar looks stale against the company's own FY26 run-rate (₹520-580 Cr/quarter), so the "beat" reflects a low preview baseline more than genuine outperformance — meanwhile actual NPM of 5.6% missed the preview's 8-9% margin watch, consistent with the compression flagged. Separately, the Board approved Arun Krishna's appointment as Additional Director (effective Aug 17, 2026) and redesignated outgoing CFO Bhavana Agrawal — who resigned July 21, 2026 for a regional AstraZeneca role — from Executive to Non-Executive Director effective September 1, 2026. Post quarter-end, the company also received a ₹148.6 Cr NPPA demand notice alleging overcharging on a respiratory drug sold between May 2016 and November 2025; management is contesting it and has booked it as a contingent liability with no provision. CFO Bhavana Agrawal said the 30% revenue growth "builds on a strong track record of consistent double-digit growth," but her quoted remarks did not address the margin decline. With operating margin down nearly 800 bps YoY and a large contingent NPPA liability outstanding, the next print will need to show whether cost pressure eases and whether the Enhertu/Fasenra oncology launches (approved Aug 7-8 and Jul 16, 2026 respectively) turn into margin-accretive volume, alongside continuity once Agrawal's CFO transition completes August 31, 2026.